DOCSLIB.ORG

Endocrinology

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Endocrinology Endocrinology Found in most species of the animal kingdom, the endocrine system consists of glands that secrete hormones, and receptors that detect and react to the hormones. In response to environmental stimuli, the endocrine system secretes hormones and uses them as chemical messengers to orchestrate physiological, developmental and reproductive changes that affect the entire body for a long period of time. In order to maintain the proper functioning of the body through its entire life cycle, the endocrine system utilizes a complex feedback mechanism to fine-tune the balance of hormones in the bloodstream. Even a slight disruption to endocrine system’s function can throw off the delicate balance of hormones in the human body and lead to an endocrine disorder, or endocrine disease, such as diabetes, adrenal insufficiency, hyper- or hypothyroidism, and polycystic ovary syndrome (PCOS). www.MedChemExpress.com 1 Endocrinology Inhibitors & Modulators (+)-PHENSERINE (9Z,11E)-Tetradecadien-1-yl acetate Cat. No.: HY-16009 (Ferodin SL; Litlure A; Prodlure) Cat. No.: HY-101735 Bioactivity: Posiphen is a novel selective cholinesterase noncompetitive Bioactivity: (9Z,11E)-Tetradecadien-1-yl acetate is the main component of the sex pheromone of female Spodoptera littoralis. inhibitor with an IC50 of 45.3 μM. Purity: >98% Purity: >98% Clinical Data: No Development Reported Clinical Data: No Development Reported Size: 250 mg, 500 mg Size: 250 mg, 500 mg 2-Thiouracil 3,3',5-Triiodo-L-thyronine (Thiouracil) Cat. No.: HY-B0503 (T3; L-3,3',5-Triiodothyronine; Liothyronine; Tresitope) Cat. No.: HY-A0070A Bioactivity: 2-Thiouracil is a thiolated uracil derivative that is a known Bioactivity: 3,3',5-Triiodo-L-thyronine is a potent agonist of thyroid antihyperthyroid agent. hormone receptors TRα and TRβ with Kis of 2.3 nM. Purity: 99.0% Purity: 98.75% Clinical Data: No Development Reported Clinical Data: Launched Size: 10mM x 1mL in DMSO, Size: 10mM x 1mL in DMSO, 1 g, 5 g 100 mg, 500 mg 3,3',5-Triiodo-L-thyronine sodium (T3 Sodium salt; Sodium 5a-Pregnane-3,20-dione L-3,3',5-triiodothyronine; Liothyronine sodium) Cat. No.: HY-A0070 Cat. No.: HY-W006492 Bioactivity: 3,3',5-Triiodo-L-thyronine sodium is an active form of thyroid Bioactivity: 5a-Pregnane-3,20-dione is the endogenous progesterone hormone, which binds to β1 thyroid hormone receptor ( metabolite. TRβ1), and activates its activity. Purity: 98.16% Purity: >98% Clinical Data: Launched Clinical Data: No Development Reported Size: 10mM x 1mL in DMSO, Size: 100 mg, 500 mg AL 082D06 Alarelin Acetate (D06; D-06) Cat. No.: HY-15709 (Alarelin) Cat. No.: HY-17405 Bioactivity: AL 082D06 is a selective, nonsteroidal glucocorticoid receptor Bioactivity: Alarelin acetate is a synthetic GnRH agonist. ( GR) antagonist with Ki of 210 nM. Purity: 98.65% Purity: 99.61% Clinical Data: No Development Reported Clinical Data: No Development Reported Size: 10mM x 1mL in DMSO, Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg 10 mg, 50 mg, 100 mg Alexamorelin Alfuzosin Cat. No.: HY-P0166 (SL 77499) Cat. No.: HY-B0192 Bioactivity: Alexamorelin is a new synthetic heptapeptide which inhibits Bioactivity: Alfuzosin is an α1 adrenergic receptor antagonist used to GHS binding in vitro. Sequence: treat benign prostatic hyperplasia (BPH). Ala-His-{Me-Trp}-Ala-Trp-Phe-Lys-NH2. Purity: 98.93% Purity: 99.81% Clinical Data: No Development Reported Clinical Data: Launched Size: 10mM x 1mL in DMSO, Size: 10mM x 1mL in DMSO, 1 mg, 5 mg, 10 mg 10 mg, 50 mg 2 Tel: 609-228-6898 Fax: 609-228-5909 Email: [email protected] Alfuzosin hydrochloride Alibendol (SL 77499-10) Cat. No.: HY-B0192A Cat. No.: HY-B0326 Bioactivity: Alfuzosin hydrochloride is an α1 adrenergic receptor Bioactivity: Alibendol is an antispasmodic,choleretic, and cholekinetic. antagonist used to treat benign prostatic hyperplasia (BPH). Purity: >98% Purity: 99.93% Clinical Data: Launched Clinical Data: Launched Size: 10 mg, 50 mg Size: 10mM x 1mL in DMSO, 100 mg, 200 mg Alrestatin Alrestatin sodium (AY-22284) Cat. No.: HY-B1202 (AY-22284A) Cat. No.: HY-B1202A Bioactivity: Alrestatin is an inhibitor of aldose reductase, an enzyme Bioactivity: Alrestatin sodium is an inhibitor of aldose reductase, an involved in the pathogenesis of complications of diabetes enzyme involved in the pathogenesis of complications of mellitus, including diabetic neuropathy. diabetes mellitus, including diabetic neuropathy. Purity: 99.14% Purity: >98% Clinical Data: No Development Reported Clinical Data: No Development Reported Size: 10mM x 1mL in DMSO, Size: 5 mg, 10 mg, 50 mg 5 mg, 10 mg, 50 mg Altrenogest Aminoguanidine hydrochloride (Pimagedine hydrochloride; (A35957; Allyltrenbolone; R2267; RU2267) Cat. No.: HY-B0521 GER-11; Aminoguanidinium chloride) Cat. No.: HY-B1041 Bioactivity: Altrenogest(A35957; RU2267) is a progestogen structurally Bioactivity: Aminoguanidine hydrochloride is a diamine oxidase and NO related to veterinary steroid trenbolone. synthase inhibitor, reduces levels of advanced glycation end products (AGEs) through interacting with 3-deoxyglucosone, is an investigational drug for the treatment of diabetic nephropathy. Purity: 98.62% Purity: 98.0% Clinical Data: No Development Reported Clinical Data: No Development Reported Size: 10mM x 1mL in DMSO, Size: 10mM x 1mL in Water, 100 mg, 500 mg 100 mg Azoramide BI 689648 Cat. No.: HY-18705 Cat. No.: HY-101217 Bioactivity: Azoramide is a small-molecule modulator of the unfolded Bioactivity: BI 689648 is a novel, highly selective aldosterone synthase protein response with antidiabetic activity. inhibitor which can inhibit CYP11B1 and CYP11B2 with IC50s of 310 and 2.1 nM, respectively. Purity: 98.0% Purity: 99.20% Clinical Data: No Development Reported Clinical Data: No Development Reported Size: 10mM x 1mL in DMSO, Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg 1 mg, 5 mg, 10 mg, 25 mg BMS-564929 BRD7552 Cat. No.: HY-12111 Cat. No.: HY-19694 Bioactivity: BMS-564929 is an androgen receptor (AR) agonist, binds to Bioactivity: BRD7552 is an inducer of transcription factor PDX1, which androgen receptor (AR) with a Ki of 2.11±0.16 nM. increases insulin expression. Purity: 98.70% Purity: 98.0% Clinical Data: No Development Reported Clinical Data: No Development Reported Size: 10mM x 1mL in DMSO, Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg 5 mg, 10 mg, 50 mg, 100 mg www.MedChemExpress.com 3 Bremelanotide Acetate Cabergoline (PT-141 Acetate) Cat. No.: HY-18678A (FCE-21336) Cat. No.: HY-15296 Bioactivity: Bremelanotide Acetate is a melanocortin agonist. IC50 value: Bioactivity: Cabergoline is an ergot derived-dopamine D 2-like receptor Target: melanocortin in vivo: Bremelanotide is a novel drug agonist that has high affinity for D , D , and 5-HT candidate for the treatment of male and female sexual 2 3 2B receptors ( K =0.7, 1.5, and 1.2, respectively). dysfunction. Bremelanotide has shown promise in effectively i treating erectile dysfunction (ED) without the cardiovascular… Purity: 98.18% Purity: 99.47% Clinical Data: Phase 3 Clinical Data: Launched Size: 10mM x 1mL in DMSO, Size: 10mM x 1mL in DMSO, 10 mg, 50 mg 5 mg, 10 mg, 50 mg Carbazole derivative 1 Carbimazole (2-Fluoro-7-[(3-pyridinyl)methyl]-9H-carbazole) Cat. No.: HY-U00323 Cat. No.: HY-B0558 Bioactivity: Carbazole derivative 1 is a carbazole derivative which can be Bioactivity: Carbimazole is an imidazole antithyroid agent. used to reduce androgen or oestrogen levels in mammals, including humans. Purity: >98% Purity: 98.0% Clinical Data: No Development Reported Clinical Data: Launched Size: 1 mg, 5 mg, 10 mg, 20 mg Size: 10mM x 1mL in DMSO, 1 g, 5 g Carvedilol CGP-53153 (BM 14190) Cat. No.: HY-B0006 Cat. No.: HY-U00125 Bioactivity: Carvedilol(BM14190) is a non-selective beta blocker/alpha-1 Bioactivity: CGP-53153 is a steroidal inhibitor of 5 alpha reductase with blocker with an IC50 of 3.8 μM for inhibition of LDL IC50s of 36 and 262 nM in rat and human prostatic tissue, oxidation. IC50 Value: 3.8 μM ( inhibition of LDL oxidation) respectively. Target: beta Adrenergic Receptor Carvedilol is a nonselective-blocking agent and is used in the treatment of… Purity: 99.93% Purity: >98% Clinical Data: Launched Clinical Data: No Development Reported Size: 10mM x 1mL in DMSO, Size: 1 mg, 5 mg, 10 mg, 20 mg 100 mg, 500 mg Chlormadinone acetate Chlorpropamide Cat. No.: HY-B1095 Cat. No.: HY-B1429 Bioactivity: Chlormadinone acetate is a steroidal progestin, with Bioactivity: Chlorpropamide is an oral antihyperglycemic agent used for the antiandrogen and antiestrogenic effects. treatment of non-insulin-dependent diabetes mellitus (NIDDM). Purity: 95.0% Purity: 99.24% Clinical Data: Launched Clinical Data: Launched Size: 10mM x 1mL in DMSO, Size: 10mM x 1mL in DMSO, 100 mg 100 mg Clomiphene citrate Cortexolone 17 alpha-propionate (Clomifene citrate) Cat. No.: HY-B0463 (Cortexolone 17α-propionate; CB-03-01) Cat. No.: HY-13331 Bioactivity: Clomifene Citrate is a selective estrogen receptor modulator. Bioactivity: Cortexolone 17 alpha-propionate(CB-03-01) is a new topical and peripherally selective androgen antagonist. Purity: 98.0% Purity: 98.76% Clinical Data: Launched Clinical Data: Phase 3 Size: 10mM x 1mL in DMSO, Size: 10mM x 1mL in DMSO, 1 g, 5 g 5 mg, 10 mg, 50 mg, 100 mg 4 Tel: 609-228-6898 Fax: 609-228-5909 Email: [email protected] Cyproterone acetate Daidzein Cat. No.: HY-13604 (Isoflavone) Cat. No.: HY-N0019 Bioactivity: Cyproterone acetate is an androgen receptor (AR) antagonist Bioactivity: Daidzein is a soy isoflavone, which acts as a PPAR activator. with IC50 of 7.1 nM, as well as a weak progesterone receptor agonist with weak pro-gestational and glucocorticoid activity. Purity: 99.71% Purity: 99.66% Clinical Data: Launched Clinical Data: Phase 4 Size: 10mM x 1mL in DMSO, Size: 10mM x 1mL in DMSO, 250 mg, 500 mg 500 mg, 1 g, 5 g, 10 g Danazol Dehydrocholic acid Cat.
Load more

Recommended publications
  • Hecate-Cgb Conjugate and Gonadotropin Suppression Shows Two Distinct Mechanisms of Action in the Treatment of Adrenocortical
    Endocrine-Related Cancer (2009) 16 549–564 Hecate-CGb conjugate and gonadotropin suppression shows two distinct mechanisms of action in the treatment of adrenocortical tumors in transgenic mice expressing Simian Virus 40 T antigen under inhibin-a promoter Susanna Vuorenoja1,2, Bidut Prava Mohanty1, Johanna Arola3, Ilpo Huhtaniemi1,4, Jorma Toppari1,2 and Nafis A Rahman1 Departments of 1Physiology and 2Pediatrics, University of Turku, Kiinamyllynkatu 10, FIN-20520 Turku, Finland 3Department of Pathology, University of Helsinki and HUSLAB, Helsinki, Finland 4Institute of Reproductive and Developmental Biology, Imperial College, London, UK (Correspondence should be addressed to N A Rahman; Email: nafis.rahman@utu.fi) Abstract Lytic peptide Hecate (23-amino acid (AA)) fused with a 15-AA fragment of human chorionic gonadotropin-b (CG-b), Hecate-CGb conjugate (H-CGb-c) selectively binds to and destroys tumor cells expressing LH/chorionic gonadotropin receptor (Lhcgr). Transgenic mice (6.5 month old) expressing SV40 T-antigen under the inhibin-a promoter (inha/Tag) presenting with Lhcgr expressing adrenal tumors were treated either with H-CGb-c, GnRH antagonist (GnRH-a), estradiol (E2; only females) or their combinations for 1 month. We expected that GnRH-a or E2 in combination with H-CGb-c could improve the treatment efficacy especially in females by decreasing circulating LH and eliminating the potential competition of serum LH with the H-CGb-c. GnRH-a and H-CGb-c treatments were successful in males (adrenal weights 14G2.8 mg and 60G26 vs 237G59 mg in controls; P!0.05). Histopathologically, GnRH-a apparently destroyed the adrenal parenchyma leaving only the fibrotic capsule with few necrotic foci.
    [Show full text]
  • The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances" WHO/EMP/RHT/TSN/2018.1
    INN Working Document 19.450 04/02/2019 Addendum1 to "The use of stems in the selection of International Nonproprietary names (INN) for pharmaceutical substances" WHO/EMP/RHT/TSN/2018.1 Programme on International Nonproprietary Names (INN) Technologies Standards and Norms (TSN) Regulation of Medicines and other health technologies (RHT) World Health Organization, Geneva © World Health Organization 2019 - All rights reserved. The contents of this document may not be reviewed, abstracted, quoted, referenced, reproduced, transmitted, distributed, translated or adapted, in part or in whole, in any form or by any means, without explicit prior authorization of the WHO INN Programme. This document contains the collective views of the INN Expert Group and does not necessarily represent the decisions or the stated policy of the World Health Organization. Addendum1 to "The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances" - WHO/EMP/RHT/TSN/2018.1 1 This addendum is a cumulative list of all new stems selected by the INN Expert Group since the publication of "The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances" 2018. ------------------------------------------------------------------------------------------------------------ -calcet/-calcet- calcium-sensing receptors (CaSR) agonists cinacalcet (88), etelcalcetide (112), evocalcet (113), tecalcet (87), upacicalcet (118) ------------------------------------------------------------------------------------------------------------
    [Show full text]
  • The Roles Played by Highly Truncated Splice Variants of G Protein-Coupled Receptors Helen Wise
    Wise Journal of Molecular Signaling 2012, 7:13 http://www.jmolecularsignaling.com/content/7/1/13 REVIEW Open Access The roles played by highly truncated splice variants of G protein-coupled receptors Helen Wise Abstract Alternative splicing of G protein-coupled receptor (GPCR) genes greatly increases the total number of receptor isoforms which may be expressed in a cell-dependent and time-dependent manner. This increased diversity of cell signaling options caused by the generation of splice variants is further enhanced by receptor dimerization. When alternative splicing generates highly truncated GPCRs with less than seven transmembrane (TM) domains, the predominant effect in vitro is that of a dominant-negative mutation associated with the retention of the wild-type receptor in the endoplasmic reticulum (ER). For constitutively active (agonist-independent) GPCRs, their attenuated expression on the cell surface, and consequent decreased basal activity due to the dominant-negative effect of truncated splice variants, has pathological consequences. Truncated splice variants may conversely offer protection from disease when expression of co-receptors for binding of infectious agents to cells is attenuated due to ER retention of the wild-type co-receptor. In this review, we will see that GPCRs retained in the ER can still be functionally active but also that highly truncated GPCRs may also be functionally active. Although rare, some truncated splice variants still bind ligand and activate cell signaling responses. More importantly, by forming heterodimers with full-length GPCRs, some truncated splice variants also provide opportunities to generate receptor complexes with unique pharmacological properties. So, instead of assuming that highly truncated GPCRs are associated with faulty transcription processes, it is time to reassess their potential benefit to the host organism.
    [Show full text]
  • Determination of Biological Activity of Gonadotropins Hcg and FSH By
    www.nature.com/scientificreports OPEN Determination of biological activity of gonadotropins hCG and FSH by Förster resonance energy transfer Received: 14 October 2016 Accepted: 06 January 2017 based biosensors Published: 09 February 2017 Olga Mazina1,2, Anni Allikalt1, Juha S. Tapanainen3, Andres Salumets2,3,4,5 & Ago Rinken1 Determination of biological activity of gonadotropin hormones is essential in reproductive medicine and pharmaceutical manufacturing of the hormonal preparations. The aim of the study was to adopt a G-protein coupled receptor (GPCR)-mediated signal transduction pathway based assay for quantification of biological activity of gonadotropins. We focussed on studying human chorionic gonadotropin (hCG) and follicle-stimulating hormone (FSH), as these hormones are widely used in clinical practice. Receptor-specific changes in cellular cyclic adenosine monophosphate (cAMP, second messenger in GPCR signalling) were monitored by a Förster resonance energy transfer (FRET) biosensor protein TEpacVV in living cells upon activation of the relevant gonadotropin receptor. The BacMam gene delivery system was used for biosensor protein expression in target cells. In the developed assay only biologically active hormones initiated GPCR-mediated cellular signalling. High assay sensitivities were achieved for detection of hCG (limit of detection, LOD: 5 pM) and FSH (LOD: 100 pM). Even the small- scale conformational changes caused by thermal inactivation and reducing the biological activity of the hormones were registered. In conclusion, the proposed assay is suitable for quantification of biological activity of gonadotropins and is a good alternative to antibody- and animal-testing-based assays used in pharmaceutical industry and clinical research. Gonadotropin medications are widely used in controlled ovarian stimulation and induction of ovulation as key components of infertility treatment.
    [Show full text]
  • Stems for Nonproprietary Drug Names
    USAN STEM LIST STEM DEFINITION EXAMPLES -abine (see -arabine, -citabine) -ac anti-inflammatory agents (acetic acid derivatives) bromfenac dexpemedolac -acetam (see -racetam) -adol or analgesics (mixed opiate receptor agonists/ tazadolene -adol- antagonists) spiradolene levonantradol -adox antibacterials (quinoline dioxide derivatives) carbadox -afenone antiarrhythmics (propafenone derivatives) alprafenone diprafenonex -afil PDE5 inhibitors tadalafil -aj- antiarrhythmics (ajmaline derivatives) lorajmine -aldrate antacid aluminum salts magaldrate -algron alpha1 - and alpha2 - adrenoreceptor agonists dabuzalgron -alol combined alpha and beta blockers labetalol medroxalol -amidis antimyloidotics tafamidis -amivir (see -vir) -ampa ionotropic non-NMDA glutamate receptors (AMPA and/or KA receptors) subgroup: -ampanel antagonists becampanel -ampator modulators forampator -anib angiogenesis inhibitors pegaptanib cediranib 1 subgroup: -siranib siRNA bevasiranib -andr- androgens nandrolone -anserin serotonin 5-HT2 receptor antagonists altanserin tropanserin adatanserin -antel anthelmintics (undefined group) carbantel subgroup: -quantel 2-deoxoparaherquamide A derivatives derquantel -antrone antineoplastics; anthraquinone derivatives pixantrone -apsel P-selectin antagonists torapsel -arabine antineoplastics (arabinofuranosyl derivatives) fazarabine fludarabine aril-, -aril, -aril- antiviral (arildone derivatives) pleconaril arildone fosarilate -arit antirheumatics (lobenzarit type) lobenzarit clobuzarit -arol anticoagulants (dicumarol type) dicumarol
    [Show full text]
  • Luteinizing Hormonereleasing Hormone (LHRH) Receptor Agonists Vs Antagonists
    Review Luteinizing hormone-releasing hormone (LHRH) receptor agonists vs antagonists: a matter of the receptors? Yuri Tolkach, Steven Joniau* and Hendrik Van Poppel* Urology Clinic, Military Medical Academy, Saint-Petersburg, Russia, and *Department of Urology, University Hospital Gasthuisberg, Katholieke Universiteit Leuven, Leuven, Belgium Luteinizing hormone-releasing hormone (LHRH) agonists and antagonists are commonly used androgen deprivation therapies prescribed for patients with advanced prostate cancer (PCa). Both types of agent target the receptor for LHRH but differ in their mode of action: agonists, via pituitary LRHR receptors (LHRH-Rs), cause an initial surge in luteinizing hormone (LH), follicle-stimulating hormone (FSH) and, subsequently, testosterone. Continued overstimulation of LHRH-R down-regulates the production of LH and leads to castrate levels of testosterone. LHRH antagonists, however, block LHRH-R signalling causing a rapid and sustained inhibition of testosterone, LH and FSH. The discovery and validation of the presence of functional LHRH-R in the prostate has led to much work investigating the role of LHRH signalling in the normal prostate as well as in the treatment of PCa with LHRH agonists and antagonists. In this review we discuss the expression and function of LHRH-R, as well as LH/human chorionic gonadotropin receptors and FSH receptors and relate this to the differential clinical responses to agonists and antagonists used in the hormonal manipulation of PCa. Keywords androgen deprivation therapy, LHRH agonist, GnRH antagonist, LHRH receptor, prostate cancer Introduction the last 30 years. LHRH agonists, by continually stimulating The most common type of treatment prescribed for the LHRH-R, down-regulate receptor expression in the patients with advanced prostate cancer (PCa) is LHRH pituitary leading to decreased levels of LH, and to a lesser agonists and these are increasingly being used in patients extent, FSH.
    [Show full text]
  • Thyrotropin-Luteinizing Hormone/Chorionic Gonadotropin
    Proc. Natl. Acad. Sci. USA Vol. 88, pp. 902-905, February 1991 Medical Sciences Thyrotropin-luteinizing hormone/chorionic gonadotropin receptor extracellular domain chimeras as probes for thyrotropin receptor function (hormone binding/signal transduction) Yuji NAGAYAMA, HARRY L. WADSWORTH, GREGORIO D. CHAZENBALK, DIEGO Russo, Pui SETO, AND BASIL RAPOPORT Thyroid Molecular Biology Unit, Veterans Administration Medical Center, San Francisco, CA 94121; and the University of California, San Francisco, CA 94143-0534 Communicated by William J. Rutter, November 2, 1990 ABSTRACT To define the sites in the extracellular domain site(s) involved in ligand binding or the region(s) important in of the human thyrotropin (TSH) receptor that are involved in signal transduction. TSH binding and signal transduction we constructed chimeric Recent studies indicate that ligand- and antibody-binding thyrotropin-luteinizing hormone/chorionic gonadotropin sites in folded globular proteins are conformational and may (TSH-LH/CG) receptors. The extracellular domain of the consist of discontinuous regions of the linear amino acid human TSH receptor was divided into five regions that were sequence (13-17). In studies defining ligand-binding sites in replaced, either singly or in various combinations, with ho- native proteins it is therefore important to conserve the mologous regions of the rat LH/CG receptor. The chimeric three-dimensional structure of the protein. The considerable receptors were stably expressed in Chinese hamster ovary cells. (30-50%) homology in the extracellular domains of the gly- The data obtained suggest that the carboxyl region of the coprotein hormone receptors together with the presence of 10 extracellular domain (amino acid residues 261418) and par- conserved extracellular cysteine residues [some ofwhich are ticularly the middle region (residues 171-260) play a role in thought to form disulfide bonds (12)] suggest a similar three- signal transduction.
    [Show full text]
  • (Hcg)- and Luteinizing Hormone (LH)-Specific
    International Journal of Molecular Sciences Article Identification of Key Receptor Residues Discriminating Human Chorionic Gonadotropin (hCG)- and Luteinizing Hormone (LH)-Specific Signaling Clara Lazzaretti 1,2, Valentina Secco 1, Elia Paradiso 1,2, Samantha Sperduti 1,3, Claudia Rutz 4, Annika Kreuchwig 4, Gerd Krause 4, Manuela Simoni 1,3,5 and Livio Casarini 1,3,* 1 Unit of Endocrinology, Department of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia, 41126 Modena, Italy; [email protected] (C.L.); [email protected] (V.S.); [email protected] (E.P.); [email protected] (S.S.); [email protected] (M.S.) 2 International PhD School in Clinical and Experimental Medicine (CEM), University of Modena and Reggio Emilia, 41125 Modena, Italy 3 Center for Genomic Research, University of Modena and Reggio Emilia, Via G. Campi 287, 41125 Modena, Italy 4 Leibniz-Forschungsinstitut für Molekulare Pharmakologie (FMP), 13125 Berlin, Germany; [email protected] (C.R.); [email protected] (A.K.); [email protected] (G.K.) 5 Department of Medical Specialties, Azienda Ospedaliero-Universitaria di Modena, 41126 Modena, Italy * Correspondence: [email protected]; Tel.: +39-339-280-0938 Abstract: (1) The human luteinizing hormone (LH)/chorionic gonadotropin (hCG) receptor (LHCGR) discriminates its two hormone ligands and differs from the murine receptor (Lhr) in amino acid residues potentially involved in qualitative discerning of LH and hCG. The latter gonadotropin is absent in rodents. The aim of the study is to identify LHCGR residues involved in hCG/LH discrimination. (2) Eight LHCGR cDNAs were developed, carrying “murinizing” mutations on aminoacidic residues assumed to interact specifically with LH, hCG, or both.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2015/0202317 A1 Rau Et Al
    US 20150202317A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2015/0202317 A1 Rau et al. (43) Pub. Date: Jul. 23, 2015 (54) DIPEPTDE-BASED PRODRUG LINKERS Publication Classification FOR ALPHATIC AMNE-CONTAINING DRUGS (51) Int. Cl. A647/48 (2006.01) (71) Applicant: Ascendis Pharma A/S, Hellerup (DK) A638/26 (2006.01) A6M5/9 (2006.01) (72) Inventors: Harald Rau, Heidelberg (DE); Torben A 6LX3/553 (2006.01) Le?mann, Neustadt an der Weinstrasse (52) U.S. Cl. (DE) CPC ......... A61K 47/48338 (2013.01); A61 K3I/553 (2013.01); A61 K38/26 (2013.01); A61 K (21) Appl. No.: 14/674,928 47/48215 (2013.01); A61M 5/19 (2013.01) (22) Filed: Mar. 31, 2015 (57) ABSTRACT The present invention relates to a prodrug or a pharmaceuti Related U.S. Application Data cally acceptable salt thereof, comprising a drug linker conju (63) Continuation of application No. 13/574,092, filed on gate D-L, wherein D being a biologically active moiety con Oct. 15, 2012, filed as application No. PCT/EP2011/ taining an aliphatic amine group is conjugated to one or more 050821 on Jan. 21, 2011. polymeric carriers via dipeptide-containing linkers L. Such carrier-linked prodrugs achieve drug releases with therapeu (30) Foreign Application Priority Data tically useful half-lives. The invention also relates to pharma ceutical compositions comprising said prodrugs and their use Jan. 22, 2010 (EP) ................................ 10 151564.1 as medicaments. US 2015/0202317 A1 Jul. 23, 2015 DIPEPTDE-BASED PRODRUG LINKERS 0007 Alternatively, the drugs may be conjugated to a car FOR ALPHATIC AMNE-CONTAINING rier through permanent covalent bonds.
    [Show full text]
  • Recent Development of Non-Peptide Gnrh Antagonists
    Review Recent Development of Non-Peptide GnRH Antagonists Feng-Ling Tukun 1, Dag Erlend Olberg 1,2, Patrick J. Riss 2,3,4, Ira Haraldsen 4, Anita Kaass 5 and Jo Klaveness 1,* 1 School of Pharmacy, University of Oslo, 0316 Oslo, Norway; [email protected] (F.-L.T.); [email protected] (D.E.O.) 2 Norsk Medisinsk Syklotronsenter AS, Postboks 4950 Nydalen, 0424 Oslo, Norway; [email protected] 3 Realomics SFI, Department of Chemistry, University of Oslo, 0316 Oslo, Norway 4 Department of neuropsychiatry and psychosomatic medicine, Oslo University Hospital, 4950 Oslo, Norway; [email protected] 5 Betanien Hospital, 3722 Skien, Norway; [email protected] * Correspondence: [email protected]; Tel.: +47-9177-6204 Received: 16 November 2017; Accepted: 4 December 2017; Published: 9 December 2017 Abstract: The decapeptide gonadotropin-releasing hormone, also referred to as luteinizing hormone-releasing hormone with the sequence (pGlu-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly-NH2) plays an important role in regulating the reproductive system. It stimulates differential release of the gonadotropins FSH and LH from pituitary tissue. To date, treatment of hormone-dependent diseases targeting the GnRH receptor, including peptide GnRH agonist and antagonists are now available on the market. The inherited issues associate with peptide agonists and antagonists have however, led to significant interest in developing orally active, small molecule, non-peptide antagonists. In this review, we will summarize all developed small molecule GnRH antagonists along with the most recent clinical data and therapeutic applications. Keywords: GnRH receptor; non-peptide GnRH antagonist 1.
    [Show full text]
  • Functional Characterization and Kinetic Studies of the Lamprey Gonadotropin
    University of New Hampshire University of New Hampshire Scholars' Repository Doctoral Dissertations Student Scholarship Winter 2005 On the neuroendocrine regulation of reproduction: Functional characterization and kinetic studies of the lamprey gonadotropin -releasing hormone receptor and cloning and analysis of the cDNA encoding lamprey gonadotropin-releasing hormone-III Matthew Ren Silver University of New Hampshire, Durham Follow this and additional works at: https://scholars.unh.edu/dissertation Recommended Citation Silver, Matthew Ren, "On the neuroendocrine regulation of reproduction: Functional characterization and kinetic studies of the lamprey gonadotropin -releasing hormone receptor and cloning and analysis of the cDNA encoding lamprey gonadotropin-releasing hormone-III" (2005). Doctoral Dissertations. 309. https://scholars.unh.edu/dissertation/309 This Dissertation is brought to you for free and open access by the Student Scholarship at University of New Hampshire Scholars' Repository. It has been accepted for inclusion in Doctoral Dissertations by an authorized administrator of University of New Hampshire Scholars' Repository. For more information, please contact [email protected]. ON THE NEUROENDOCRINE REGULATION OF REPRODUCTION: FUNCTIONAL CHARACTERIZATION AND KINETIC STUDIES OF THE LAMRPEY GONADOTROPIN-RELEASING HORMONE RECEPTOR AND CLONING AND ANALYSIS OF THE cDNA ENCODING LAMPREY GONADOTROPIN-RELEASING HORMONE-III BY MATTHEW REN SILVER B.S., University of Connecticut, 2000 DISSERTATION Submitted to the University of New Hampshire in Partial Fulfillment of the Requirements for the Degree of Doctor of Philosophy In Biochemistry December, 2005 Reproduced with permission of the copyright owner. Further reproduction prohibited without permission. UMI Number: 3198014 INFORMATION TO USERS The quality of this reproduction is dependent upon the quality of the copy submitted.
    [Show full text]
  • First Principles and Their Application to Drug Discovery
    REVIEWS Drug Discovery Today Volume 17, Numbers 1/2 January 2012 The utilization of the kinetic and thermodynamic signatures of preclinical leads is proving pivotal in their triage and rational optimization towards clinical candidates with maximal in vivo efficacy devoid of adverse events. Reviews KEYNOTE REVIEW Target–drug interactions: first principles and their application to drug discovery 1 1 Sara Nu´n˜ez studied organic Sara Nu´n˜ ez , Jennifer Venhorst and Chris G. Kruse chemistry at the University of Barcelona (Spain) and the Abbott Healthcare Products, 1381 CP Weesp, The Netherlands University of London (UK). She received her Ph.D. in 2003 from the University of Manchester (UK), and thereafter did a In this review, we begin by introducing the basic principles of kinetics postdoc in Biophysics at the and thermodynamics of target–drug binding within the context of Albert Einstein College of Medicine (USA). In 2005, she drug discovery. In addition, we present a meta-analysis of the recent joined Solvay Pharmaceuticals (now Abbott Healthcare) in The Netherlands as a postdoctoral fellow; and in 2008, she literature describing the kinetic and thermodynamic resolution of was promoted to Sr. Computational Medicinal Chemist. At Abbott, she has supported the medicinal chemistry efforts successful clinical candidates with diverse mechanisms of action. for neuroscience drug discovery programs, from target We finish by discussing the best practices in the triage and chemical discovery up to and including clinical proof of principle studies. She has supported more than 15 programs optimization towards clinical candidates with maximal in vivo internationally, and was project manager of the D2-103 Top Institute Pharma innitiative.
    [Show full text]